Aktienanalyse zu Aquestive Therapeutics, Inc. (AQST)AQSTAquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, Aquestive Therapeutics Inc (AQST) is not a strong buy. The stock is priced at $4, with a low RSI of 34.584 indicating it is oversold, but the forward P/E ratio is 0, reflecting uncertainty about future earnings. The recent positive news regarding the NDA resubmission for Anaphylm shows potential, but the company has a significant net loss of $22.9 million in Q2 2026, which raises concerns about its financial health. The insider selling has increased by 140.84%, suggesting a lack of confidence from those closest to the company, which is a major risk.

4 analysts cover AQST: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 9.00.